About: Transparent Development of the WHO Rapid Advice Guidelines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transparent Development of the WHO Rapid Advice Guidelines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transparent Development of the WHO Rapid Advice Guidelines
Creator	Farrar, Jeremy Yazdanpanah, Yazdan Stockman, Lauren Hayden, Frederick Bellamy, Richard Uyeki, Timothy Beigel, John Chotpitayasunondh, Tawee Kakad, Meetali Sugaya, Norio Zucker, Howard Hien, Tran Hill, Suzanne Oxman, Andrew Schünemann, Holger Mar, Chris Vist, Gunn Fosen Wisløff, Torbjørn
Source	Medline; PMC
abstract	Emerging health problems require rapid advice. We describe the development and pilot testing of a systematic, transparent approach used by the World Health Organization (WHO) to develop rapid advice guidelines in response to requests from member states confronted with uncertainty about the pharmacological management of avian influenza A (H5N1) virus infection. We first searched for systematic reviews of randomized trials of treatment and prevention of seasonal influenza and for non-trial evidence on H5N1 infection, including case reports and animal and in vitro studies. A panel of clinical experts, clinicians with experience in treating patients with H5N1, influenza researchers, and methodologists was convened for a two-day meeting. Panel members reviewed the evidence prior to the meeting and agreed on the process. It took one month to put together a team to prepare the evidence profiles (i.e., summaries of the evidence on important clinical and policy questions), and it took the team only five weeks to prepare and revise the evidence profiles and to prepare draft guidelines prior to the panel meeting. A draft manuscript for publication was prepared within 10 days following the panel meeting. Strengths of the process include its transparency and the short amount of time used to prepare these WHO guidelines. The process could be improved by shortening the time required to commission evidence profiles. Further development is needed to facilitate stakeholder involvement, and evaluate and ensure the guideline's usefulness.
has issue date	2007-05-29(xsd:dateTime)
bibo:doi	10.1371/journal.pmed.0040119
bibo:pmid	17535099
has license	cc0
sha1sum (hex)	8275311de465e4fdbb25ebddf76302cd4603c36c
schema:url	https://doi.org/10.1371/journal.pmed.0040119
resource representing a document's title	Transparent Development of the WHO Rapid Advice Guidelines
has PubMed Central identifier	PMC1877972
has PubMed identifier	17535099
schema:publication	PLoS Med
resource representing a document's body	covid:8275311de465e4fdbb25ebddf76302cd4603c36c#body_text
is schema:about of	named entity 'ADVICE' named entity 'TRANSPARENT' named entity 'GUIDELINES' named entity 'RAPID' named entity 'DEVELOPMENT' named entity 'GRADE approach' named entity 'e119' named entity 'pharmacological' named entity 'H5N1' named entity 'WHO' named entity 'methodologists' named entity 'H5N1' named entity 'health problem' named entity 'medical literature' named entity 'case series' named entity 'H5N1' named entity 'infection' named entity 'virus' named entity 'electronic discussion list' named entity 'oseltamivir' named entity 'emerging disease' named entity 'WHO' named entity 'middle-income' named entity 'H5N1' named entity 'cation' named entity 'United Kingdom' named entity 'pharmacological' named entity 'virus infection' named entity 'design and development' named entity 'severe acute respiratory syndrome' named entity 'public health' named entity 'H5N1' named entity 'WHO' named entity 'prophylaxis' named entity 'design and development' named entity 'pilot testing' named entity 'emerging infectious diseases' named entity 'SARS' named entity 'H5N1' named entity 'pharmacological' named entity 'GRADE' named entity 'virus infection' named entity 'antivirals' named entity 'WHO' named entity 'animal studies' named entity 'design and development' named entity 'decision makers' named entity 'chemoprophylaxis' named entity 'H5N1' named entity 'WHO' named entity 'clinical trials' named entity 'World Health Organization' named entity 'email' named entity 'middle-income' named entity 'systematic reviews' named entity 'decision making' named entity 'H5N1' named entity 'GRADE approach' named entity 'H5N1' named entity 'methodologists' named entity 'decision making' named entity 'adverse effects' named entity 'virus' named entity 'randomized trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software